This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

QBI-139

Quintessence Biosciences, Inc.

Drug Names(s): QBI-139

Description: QBI-139 is variant of a human ribonuclease (RNase)that has diminished binding to its natural intracellular inhibitor. QBI-139 retains 95% sequence identity to a naturally occurring RNase.

The drug is based on the company's EVade Ribonuclease technology which generates analogs of the human pancreatic ribonuclease 1.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug